HKEX Stock Code: 01093English|繁體|简体

Highlight - 2026 Interim Results

Revenue
RMB18,594M, +40.1%
Reported profit attributable to shareholders of the Company
RMB6,094M, +139.2%
Underlying profit attributable to shareholders of the Company
RMB6,164M, +165.8%
Basic earnings per share (based on reported profit attributable to shareholders of the Company)
RMB53.45 cents, +139.8%

Key Products

Finished drugs
Bulk drugs
© Copyright 2026 CSPC Pharmaceutical Group Limited. All Rights Reserved.